GlassScriptPhysician profile
Leroy O Jeske
NPI 1205839446
$1,199.64
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $298 · 2021: $420 · 2022: $184.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $140.20 | 2019-2021 | |
| Amgen INC. | $124.92 | 2019-2021 | |
| Abbvie INC. | $101.22 | 2020-2022 | |
| Abbott Laboratories | $86.61 | 2019-2022 | |
| Amarin Pharma, INC. | $76.99 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $53.64 | 2021-2022 | |
| Glaxosmithkline, LLC. | $44.29 | 2019-2020 | |
| Nevro Corp. | $43.04 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $42.82 | 2019-2022 | |
| Lilly USA, LLC | $42.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.26 | 2019-2020 | |
| Daiichi Sankyo INC. | $38.37 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.61 | 2021 | |
| Currax Pharmaceuticals LLC | $28.38 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $27.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.98 | 2021 | |
| Pfizer INC. | $26.73 | 2021-2022 | |
| Alk-Abello, INC | $24.45 | 2019 | |
| Esperion Therapeutics, INC. | $19.54 | 2021 | |
| Sanofi Pasteur INC. | $18.73 | 2021 | |
| Allergan, INC. | $17.82 | 2019 | |
| Mylan Specialty L.P. | $17.06 | 2019 | |
| Aytu Biopharma, INC. | $14.21 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2020 | |
| Althera Pharmaceuticals LLC | $13.35 | 2021 | |
| Astellas Pharma US INC | $13.02 | 2021 | |
| Merck Sharp & Dohme LLC | $12.69 | 2021 | |
| Eisai INC. | $11.23 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leroy Jeske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.